Accession Number:

ADA551381

Title:

Use of Synthetic Antibodies Targeted to the Jak/Stat Pathway in Breast Cancer

Descriptive Note:

Annual rept. 15 Feb 2009-14 Feb 2010

Corporate Author:

NORTHWESTERN UNIV EVANSTON IL

Personal Author(s):

Report Date:

2010-03-01

Pagination or Media Count:

5.0

Abstract:

This proposal seeks to generate SABs synthetic antigen binders against the PRLr prolactin receptor signaling complex to systematically inhibit and modulate its important activities in breast cancer. This complex has clearly been demonstrated to play a significant role in the development and spread of this disease, and yet the generation of pharmacologic agents that can specifically block their function has been slow. We hypothesize that SABs can be rapidly generated to the PRLr, CypA, CypB, Jak2, Stat3, and Stat5 and delivered into the cell, where these reagents will block breast cancer cell growth, survival, and spread. We have successfully generated phage to Cyp A and B, and have begun to characterize SAB against the PRLr. It is the intent of this proposal to validate the efficacy of these highly innovative reagents on a panel of breast cancer cells in vitro, with future translation into pre-clinical testing.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE